Details for Patent: 9,713,599
Summary for Patent: 9,713,599
| Title: | Parenteral formulations of treprostinil |
| Abstract: | The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Michael Wade |
| Assignee: | United Therapeutics Corp |
| Application Number: | US14/629,938 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; |
Drugs Protected by US Patent 9,713,599
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,713,599
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | 473736 | ⤷ Start Trial | |||
| Canada | 2549724 | ⤷ Start Trial | |||
| China | 101647792 | ⤷ Start Trial | |||
| China | 1917866 | ⤷ Start Trial | |||
| Germany | 602004028155 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
